Heart rate variability - A therapeutic target?

Journal of Clinical Pharmacy and Therapeutics

Volumn 27, Issue 2, 2002, Pages 85-92

  Routledge, H C ^a   Chowdhary, S ^a   Townend, J N ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

ACE inhibitors; Autonomic nervous system; Baroreflex sensitivity; Beta blockers; Heart rate variability; Sudden death

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; METOPROLOL; SCOPOLAMINE; SPIRONOLACTONE;

ARTICLE; CLINICAL TRIAL; DRUG EFFECT; EXERCISE; HEART ARRHYTHMIA; HEART FAILURE; HEART FUNCTION; HEART MUSCLE OXYGEN CONSUMPTION; HEART RATE VARIABILITY; HUMAN; MORTALITY; NONHUMAN; PROGNOSIS; SUDDEN DEATH; SYMPATHETIC TONE; VAGUS NERVE STIMULATION;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; AUTONOMIC NERVOUS SYSTEM; DEATH, SUDDEN, CARDIAC; DISEASE MODELS, ANIMAL; HEART DISEASES; HEART RATE; HUMANS; PROGNOSIS; RISK FACTORS; VAGUS NERVE;

EID: 0036252412     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.2002.00404.x     Document Type: Article

References (73)

1. Prospective study of heart rate variability and mortality in chronic heart failure: Results of the United Kingdom heart failure evaluation and assessment of risk trial (U.K.-heart)
2. Time course of recovery of heart period variability after myocardial infarction
3. Heart rate variability in the early hours of an acute myocardial infarction
4. Baroreflex sensitivity
5. Power spectral analysis of cardiovascular variability in patients at risk for sudden cardiac death
6. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction
7. Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias
8. Impact of reduced heart rate variability on risk for cardiac events
9. Sympathetic and parasympathetic cardiac control in athletes and nonathletes at rest
10. Heart rate variability: Standards of measurement, physiological interpretation and clinical use
11. Human sinus arrhythmia as an index of vagal cardiac outflow
12. Respiratory sinus arrhythmia: Noninvasive measure of parasympathetic cardiac control
13. Assessment of autonomic function in humans by heart rate spectral analysis
14. Vagus nerve stimulation decreases left ventricular contractility in vivo in the human and pig heart
15. Inhibition by acetylcholine of adrenergic neurotransmission in vascular smooth muscle
16. Muscarinic receptors involved in modulation of norepinephrine release and vasodilatation in guinea pig carotid arteries
17. A muscarinic inhibition of the noradrenaline release evoked by postganglionic sympathetic nerve stimulation
18. Muscarinic cholinergic receptor modulation of beta-adrenoreceptor affinity for catecholamines
19. Adrenergic effects on the biology of the adult mammalian cardiocyte
20. Opposing effects of b1- and b2-adrenergic receptors on cardiac myocyte apoptosis. Role of a pertussis-toxin sensitive G protein
21. Autonomic mechanisms and sudden death. New insights from analysis of baroreceptor reflexes in conscious dogs with and without a myocardial infarction
22. Vagal stimulation and prevention of sudden death in conscious dogs with a healed myocardial infarction
23. Pharmacologic modulation of the autonomic nervous system in the prevention of sudden cardiac death. A Study with propranolol, methacholine and oxotremorine in conscious dogs with a healed myocardial infarction
24. Electrical stability of acutely ischemic myocardium. Influences of heart rate and vagal stimulation
25. Role of the vagus nerves in the cardiovascular changes induced by coronary occlusion
26. Neural activity and ventricular fibrillation
27. Prevention of life-threatening arrhythmias by pharmacologic stimulation of the muscarinic receptors with oxotremorine
28. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II)
29. The mortality effect of metoprolol CR/XL in patients with heart failure: Results of the MERIT-HF trial
30. The Survival and Ventricular Enlargement (SAVE) Study: Rationale and perspective
31. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure
32. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure
33. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
34. Beta-adrenergic blockade may prolong life in post-infarction patients in part by increasing vagal cardiac inhibition
35. Central beta-adrenergic mechanisms may modulate ischemic ventricular fibrillation in pigs
36. Role of central nervous beta-adrenoceptors in the prevention of ventricular fibrillation through augmentation of cardiac vagal tone
37. Use of opposing reflex stimuli and heart rate variability to examine the effects of lipophilic and hydrophilic beta-blockers on human cardiac vagal control
38. Effect of beta-blockade on baroreceptor and autonomic function in heart failure
39. Long-term beta-blocker therapy improves autonomic nervous regulation in advanced congestive heart failure: A longitudinal heart rate variability Study
40. Effects of bisoprolol on heart rate variability in heart failure
41. The effects of metoprolol given early in acute myocardial infarction on ventricular arrhythmias
42. A double-blind trial of metoprolol in acute myocardial infarction. Effects on ventricular tachyarrhythmias
43. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial
44. Amiodarone interaction with beta-blockers
45. The role of beta receptor blockade in preventing sudden death
46. Inhibition by angiotensin II of baroreceptor-evoked activity in cardiac vagal efferent nerves in the dog
47. Angiotensin inhibits action of vagus nerve at the heart
48. Intravertebral angiotensin II inhibits cardiac vagal efferent activity in dogs
49. Modulation of cardiac autonomic control in humans by angiotensin II
50. ACE inhibition improves vagal reactivity in patients with heart failure
51. Effect of quinapril on blood pressure and heart rate in congestive heart failure
52. Effect of captopril on cardiac parasympathetic activity in chronic cardiac failure secondary to coronary artery disease
53. Sustained augmentation of parasympathetic tone with angiotensin-converting enzyme inhibition in patients with congestive heart failure
54. Effects of converting enzyme inhibition on heart period variability in patients with acute myocardial infarction
55. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction
56. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction
57. Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: The Hy-C trial
58. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure
59. Aldosterone reduces baroreceptor discharge in the dog
60. Aldosterone blunts the baroreflex response in man
61. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients
62. Controlled trial of physical training in chronic heart failure. Exercise performance, hemodynamics, ventilation, and autonomic function
63. Reversal of autonomic derangements by physical training in chronic heart failure assessed by heart rate variability
64. Circadian pattern of heart rate variability in chronic heart failure patients. Effects of physical training
65. Exercise training confers anticipatory protection from sudden death during acute myocardial ischemia
66. Respiratory sinus arrhythmia and central respiratory drive in humans
67. Opposing central and peripheral effects of atropine on parasympathetic cardiac control
68. Influence of transdermal scopolamine on cardiac sympathovagal interaction after acute myocardial infarction
69. Scopolamine increases vagal tone and vagal reflexes in patients after myocardial infarction
70. Low doses of scopolamine increase cardiac vagal tone in the acute phase of myocardial infarction
71. Effect of low doses of scopolamine on RR interval variability, baroreflex sensitivity, and exercise performance in patients with chronic heart failure
72. Scopolamine improves autonomic balance in advanced congestive heart failure
73. Do increases in markers of vagal activity imply protection from sudden death?. The case of scopolamine